Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. develops clinical-stage neuroplastogen-derived therapeutics focused on mental health and substance-use disorders. News for CMND centers on CMND-100, the company's proprietary non-hallucinogenic MEAI-based oral drug candidate for Alcohol Use Disorder, including clinical-trial safety, tolerability, pharmacokinetic and preliminary efficacy updates from a multinational Phase I/IIa study.
Company updates also cover intellectual-property activity for psychedelic and neuroplastogen compounds, including patent applications and licensed development rights tied to PTSD and other mental health disorders. Additional recurring themes include FDA-related clinical communications, data-safety monitoring reviews, clinical-site progress and scientific presentations around MEAI.
Clearmind Medicine (Nasdaq: CMND) reported ex vivo mucoadhesion data showing its intranasal formulation of MEAI (5‑Methoxy‑2‑aminoindane) maintained higher nasal tissue residence than a non‑mucoadhesive MEAI solution. Using freshly isolated rabbit nasal mucosa over a 30‑minute test, the intranasal formulation consistently retained a greater proportion of its initially adhered dose.
According to Clearmind, enhanced nasal residence time is a key objective of its intranasal MEAI development program for Alcohol Use Disorder, aiming to counter rapid mucociliary clearance and support more consistent dosing. The positive retention profile supports the role of the mucoadhesive polymer system and further validates Clearmind’s nasal drug‑delivery platform.
Clearmind Medicine (Nasdaq: CMND) shared real-world insights from its ongoing first-in-human Phase I/IIa trial of CMND-100, a non-hallucinogenic MEAI-based compound for Alcohol Use Disorder (AUD), following a June 10 “Inside MEAI” webinar featuring principal investigators from Yale and Johns Hopkins.
According to Clearmind, investigators reported a generally positive early impression of CMND‑100, emphasizing MEAI’s non-hallucinogenic profile, which may support a simpler, more accessible treatment model without hospitalization, intensive monitoring, or mandatory psychological supervision. They also noted improved blinding versus classical psychedelics, good recruitment progress despite strict eligibility criteria, and a promising early safety profile with no meaningful adverse effects or cardiac safety concerns observed to date. The session also discussed study design, dose escalation, pharmacokinetics, participant experience, and potential applications of MEAI beyond AUD that will require further research.
Clearmind Medicine (Nasdaq: CMND) submitted a formal response to a U.S. Department of Health and Human Services Request for Information under the Great American Recovery Initiative, outlining MEAI’s potential as an empirically supported, non-hallucinogenic treatment for addiction, especially Alcohol Use Disorder (AUD).
The company highlights CMND-100, its proprietary MEAI-based neuroplastogen candidate for AUD and binge behaviors, designed as a scalable, at-home, FDA-regulated therapy with low abuse potential. Clearmind notes AUD affects about 10% of Americans, with only 1 in 10 receiving treatment, and positions neuroplastogen-based therapies as compatible with community, rural, and underserved settings.
Clearmind (Nasdaq: CMND) reported successful formulation-feasibility results for intranasal delivery of its lead candidate MEAI, initially aimed at treating alcohol use disorder (AUD).
The study showed MEAI can be stably incorporated into an intranasal formulation as a fully soluble solution, supporting continued development of this additional route of administration.
Clearmind Medicine (Nasdaq: CMND) announced grant of U.S. Patent No. 12,357,590, titled “BINGE BEHAVIOR REGULATORS,” by the USPTO.
The patent builds on U.S. Patent No. 12,350,242 and expands intellectual property protection around the MEAI molecule for regulating binge behaviors and compulsive disorders.
Clearmind Medicine (Nasdaq: CMND) completed treatment for all 24 participants in Part A of its FDA‑regulated Phase I/II trial of CMND‑100 for Alcohol Use Disorder (AUD). The multicenter study spans four cohorts at leading sites in the United States and Israel.
Clearmind is reviewing the dataset and, if results remain favorable, plans to initiate the next stage of the AUD clinical program.
Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech, received U.S. patent No. 12,350,242 titled “BINGE BEHAVIOR REGULATORS” from the USPTO.
The patent covers MEAI-based compositions using pharmaceutically acceptable salts to regulate binge behaviors and lifts Clearmind’s global portfolio to 32 granted patents, supporting programs like CMND-100 for binge-related and CNS disorders.
Clearmind Medicine (Nasdaq: CMND) reported completion of dosing for all 24 participants in Cohorts 1–4 (Part A) of its FDA-regulated Phase I/II trial of CMND-100 for Alcohol Use Disorder. The multicenter, randomized, double-blind, placebo-controlled study uses escalating doses in healthy participants.
According to Clearmind, interim data from the first three cohorts continue to indicate a strong safety profile, supported by rapid enrollment and efficient execution at Yale, Johns Hopkins, Tel Aviv Sourasky, and Hadassah Medical Center sites.
Clearmind Medicine (Nasdaq: CMND) will host a live webinar, “Inside MEAI: Exclusive Investigator Q&A with Yale & Johns Hopkins,” on June 10, 2026, from 12:00–1:00 PM EDT.
The event will review early clinical data from the FDA-approved Phase I/IIa multi-center trial of CMND-100, a non-hallucinogenic MEAI-based oral candidate for Alcohol Use Disorder. Yale’s Dr. Anahita Bassir Nia and Johns Hopkins’ Dr. Jennifer Ellis will discuss findings, while CEO Dr. Adi Zuloff-Shani provides a clinical and corporate update. The webinar, moderated by Shannon Smadella, is free, open to the public, and requires Eventbrite registration.
Clearmind Medicine (Nasdaq: CMND) reported a Japanese patent application publication for MEAI-based compositions targeting depression, expanding its global intellectual property portfolio. MEAI is a non-hallucinogenic molecule intended as an alternative to SSRIs and psychedelic-based therapies.
The company highlights large and growing anxiety, depression, and broader behavioral health markets, including an estimated $16–22.65 billion global anxiety and depression market in 2025. Japan has about 3 million diagnosed MDD cases. Clearmind is also researching MEAI for alcohol use disorder, metabolic disorders such as weight loss, and other mental health indications.